Cipla Limited (CIPLA)
Please find enclosed disclosure
Cipla received US FDA approval for Generic Advair Diskus® in all three strengths (100/50 mcg, 250/50 mcg, 500/50 mcg).
- Product is a therapeutically equivalent version for asthma and COPD treatment.
- US market size approx. $908 million for this inhalation powder.
- First dry powder inhaler approval from Cipla's US manufacturing network.
- Launch expected in Q2 FY 2026-27 in the USA.
- Approval marks milestone in Cipla's complex respiratory capabilities expansion in the US.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 CIPLA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add CIPLA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Cipla Limited
Important.
The summary above is generated automatically from Cipla Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.